FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Young Jonathan
2. Issuer Name and Ticker or Trading Symbol

Akero Therapeutics, Inc. [ AKRO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Operating Officer
(Last)          (First)          (Middle)

C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350
3. Date of Earliest Transaction (MM/DD/YYYY)

1/7/2022
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/7/2022  M  27744 A$0.615 163254 D  
Common Stock         20000 I By EA Irrevocable Trust (1)
Common Stock         20000 I By CM Irrevocable Trust (1)
Common Stock         20000 I By JL Irrevocable Trust (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy) $0.615 1/7/2022  M     26296   (2)7/29/2028 Common Stock 26296 $0 0 D  
Employee Stock Option (Right to Buy) $0.615 1/7/2022  M     1448   (3)10/17/2028 Common Stock 1448 $0 92820 D  

Explanation of Responses:
(1) These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
(2) 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.
(3) Shares vested and became exercisable in equal monthly installments for a period of 48 months following October 1, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Young Jonathan
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080


Chief Operating Officer

Signatures
/s/ Jonathan Young1/11/2022
**Signature of Reporting PersonDate

Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Akero Therapeutics Charts.
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Akero Therapeutics Charts.